Producer
Macfarlan Smith Ltd. (Esteve Pharmaceuticals)
UK pharmaceutical API manufacturer (HQ Edinburgh, Scotland; owned by Esteve Pharmaceuticals, Barcelona Spain); the UK's primary opioid alkaloid API producer and one of Europe's most significant buprenorphine API manufacturers. Macfarlan Smith's Edinburgh, Scotland site — operating since 1815 as a morphine and opium alkaloid processor — is the primary EU/UK source of buprenorphine API, codeine, morphine, hydromorphone, and other opioid alkaloid APIs. The Edinburgh facility processes raw opium alkaloids into pharmaceutical-grade narcotics under UK Home Office controlled substance licensing and INCB annual quota allocations. Macfarlan Smith supplies buprenorphine API to European generic pharmaceutical manufacturers and historically supplied Reckitt Benckiser (now Indivior) for Suboxone and Subutex manufacturing in Europe. Esteve Pharmaceuticals (Barcelona) acquired Macfarlan Smith from Johnson Matthey in 2015, adding UK opioid API manufacturing to its Spanish pharmaceutical business. The Edinburgh site is a UNESCO Industrial Heritage-adjacent facility — one of the oldest continuous pharmaceutical manufacturing sites in the world.
2
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs Macfarlan Smith Ltd. (Esteve Pharmaceuticals) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Macfarlan Smith Ltd. (Esteve Pharmaceuticals) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Buprenorphine API (Addiction Treatment)
40%Morphine & Codeine APIs
35%Specialty Opioid APIs
25%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2022
Macfarlan Smith in Edinburgh is the only manufacturer in the United Kingdom licensed to produce pharmaceutical diamorphine — pharmaceutical-grade heroin used for severe pain management in NHS palliative care and for heroin-assisted treatment (HAT) programs in a handful of UK clinics treating heroin use disorder. Pharmaceutical diamorphine is synthesized from morphine (via acetylation), which itself derives from Macfarlan Smith's alkaloid processing of poppy straw. The UK is one of very few countries in the world that maintains a legal pharmaceutical diamorphine supply chain for medical use. Macfarlan Smith therefore simultaneously produces: naloxone (reverses opioid overdose), buprenorphine (treats opioid use disorder), and diamorphine (pharmaceutical heroin for pain management and HAT programs) — from the same Edinburgh facility, from the same alkaloid source, under the same INCB quota framework. A single manufacturing site disruption in Edinburgh would simultaneously affect supply of the most stigmatized pharmaceutical (heroin), the most praised public health intervention (Narcan), and the most effective addiction treatment (Suboxone).
Macfarlan Smith Ltd ↗Incident2023
[single-source] Macfarlan Smith's Edinburgh opioid API site has been operating continuously since 1815 — through the Napoleonic Wars, the Industrial Revolution, two World Wars, and the modern opioid epidemic response. The site was founded as a morphine and opium processing operation when laudanum (opium tincture) was sold over-the-counter in Britain for pain, cough, and infant colic. Over 200 years, the same Edinburgh facility transitioned from processing raw opium to producing purified morphine (19th century), then to semi-synthetic derivatives like codeine (early 20th century), hydromorphone and oxycodone (mid-20th century), and finally buprenorphine (late 20th-21st century). The facility Johnson Matthey acquired in the 1970s and operated as a pharmaceutical subsidiary was sold to Esteve Pharmaceuticals (Barcelona) in 2015 for an undisclosed sum. The Edinburgh site is among the oldest continuously operating pharmaceutical manufacturing sites in the world — and its core product progression mirrors the history of opioid medicine itself.
Macfarlan Smith Ltd. ↗Origin2023
Macfarlan Smith traces its pharmaceutical chemistry roots to Edinburgh in the mid-19th century — the height of Edinburgh's prominence as Europe's leading medical education and pharmaceutical science city (Edinburgh Medical School produced many of the 19th century's most important pharmacologists). The company has produced pharmaceutical alkaloids from natural plant sources for over 150 years, surviving through the era when morphine was sold as a patent medicine, through WWI and WWII when pharmaceutical alkaloids were critical military drugs, through the regulatory development of the modern controlled substances framework, and through the opioid epidemic era. It was acquired by Esteve Pharmaceuticals (Barcelona, Spain) in the 2000s, embedding a Scottish pharmaceutical heritage company into a Spanish pharmaceutical group.
Macfarlan Smith Ltd ↗